Arcus Biosciences And Gilead Discontinue Phase 3 STAR-221 Study In Cancer Due To Futility

Arcus Biosciences and partner Gilead have discontinued the Phase 3 STAR-221 trial after an Independent Data Monitoring Committee recommended stopping for futility when a pre-specified interim analysis found domvanalimab plus zimberelimab and chemotherapy did not improve overall survival versus nivolumab plus chemotherapy; safety profiles were similar. Arcus said it will reallocate resources to its casdatifan HIF-2α program—where it retains rights outside Japan and certain Asian territories (Taiho holds options)—with multiple data readouts expected in 2026, alongside five inflammatory/autoimmune programs and a planned 2026 clinic entry for an MRGPRX2 small molecule. The company reported roughly $1 billion in cash and investments, which it expects will fund operations into at least the second half of 2028.

Analysis

Arcus Biosciences and partner Gilead discontinued the Phase 3 STAR-221 study after an Independent Data Monitoring Committee recommended stopping for futility when a pre-specified interim overall survival analysis found domvanalimab plus zimberelimab and chemotherapy did not improve OS versus nivolumab plus chemotherapy; the safety profile was reported as similar between arms. This outcome removes a near-term potential approval pathway for Arcus's TIGIT program and represents a clear clinical setback relative to the comparator regimen.

Management is reallocating resources to casdatifan, a HIF-2α inhibitor in which Arcus retains rights outside Japan and certain Asian territories (those rights were optioned by Taiho in October 2025), and expects multiple casdatifan data readouts in 2026; the company also plans five inflammatory/autoimmune programs and an MRGPRX2 small molecule entering the clinic in 2026. These program timelines create several binary value inflection points next year.

Arcus reports approximately $1.0 billion in cash and investments, which it expects will fund operations into at least the second half of 2028, reducing immediate financing pressure. Market signals show moderately negative sentiment with greater pressure on RCUS than GILD; investors should weigh the dilution and repricing risk from lost oncology upside against the 2026 clinical catalysts and the stated cash runway.

Key Decisions for Investors

• Reduce or hedge direct exposure to RCUS until 2026 casdatifan and MRGPRX2 readouts reduce binary clinical risk
• Monitor the specific 2026 data readout timelines and topline metrics for casdatifan closely, as positive results could materially re-rate the stock
• Track quarterly cash burn and guidance against the stated ~$1 billion runway to H2 2028 to assess dilution risk and need for financing
• For GILD investors, no immediate portfolio action is necessary beyond watching partner commentary, as Gilead appears less affected by the trial discontinuation